180 results about "Flavolipin" patented technology

A flavin-binding glucose dehydrogenase with a high substrate specificity for D-glucose. The flavin-binding glucose dehydrogenase which is derived from a microorganism belonging to the genus Mucor. The flavin-binding glucose dehydrogenase has a low reactivity for maltose, D-galactose and D-xylose compared to its reactivity for D-glucose, and therefore is relatively unaffected by these saccharide compounds. The flavin-binding glucose dehydrogenase is also relatively unaffected by dissolved oxygen, and allows accurate measurement of glucose amounts even in the presence of saccharide compounds other than glucose in samples.

The present invention relates to a Soy daidzin composition and its preparation method and application. It provides three compounds containing isoflavone glucoside which can be used for preparing medicine for curing climacteric syndrome due to female hormone deficiency and middle-aged and senile obtiterating angiocardiopathy and cerebrovascular disease. Said composition contains isoflavone glucoside compound, i.e. diadzin, soyabean flaving glucoside and genistin, and three kinds of isoflavone are 90%-100% of the composition, and the ratio of three isoflavone glucoside is 2-3:1-2:3-4. It can be made into various dosage forms of medicine preparation, and its preparation method includes the following steps: extracting soyabean with ethyl alcohol, concentrating, extracting with petroleum ether, vacuum drying to obtain dried powder.

The invention belongs to the field of bioengineering and particularly relates to a flavin monooxygenase mutant and a preparation method thereof. The error-prone PCR technology is used to conduct random mutation on wild type flavin monooxygenase to obtain the flavin monooxygenase mutant. The specific enzyme activity of the flavin monooxygenase mutant is improved by 35% compared with that of the wild type flavin monooxygenase. Meanwhile, a yeast expression system is adopted, when the flavin monooxygenase is displayed on the surface of yeasts, yeast cells can serve as enzyme producers and can also serve as carriers in immobilized enzymes, operation of purification, fixation and the like of the enzymes are omitted, the production link is simplified, and the production cost is reduced.

The invention provides application of monascus color components and derivatives thereof in preparing the drugs for fighting cancers, belonging to the technical field of monascus compound application. The invention solves the problem of narrower application range of the monascus color components and derivatives thereof in the prior art. The series compound comprises rubropunctamine, monascorubramine, monascin, ankaflavin, rubropunctatin, monascorubrine, monasfluore A, monasfluore B and derivatives thereof. The compound can be used as the drug and health care product additive for preventing and treating cancers and has little toxic or side effects on normal cells of human bodies.

The invention discloses a method for preparing questin by utilizing an ocean aspergillus flavipes HN4-13 bacterial strain. The method comprises the following steps: conducting separation and purification on antibacterial active substances generated through fermentation of the aspergillus flavipes HN4-13 bacterial strain according to silica-gel column chromatography, Sephadex LH-20 column chromatography, preparation of high performance liquid chromatography (PHPLC) and the like by taking vibrio harveyi as an indicator bacterium, so as to obtain a vibrio harveyi-preventing active compound HY2; indentifying the structure of the active compound HY2 according to spectra data such as ESI-MS, 1H-NMR and 13C-NMR, so as to determine that the active compound HY2 is questin. The questin is obtained through separation of a metabolic product of aspergillus flavipes HN4-13; experiments show that the questin can perform a certain inhibiting function of the pathogenic bacteria, such as vibrio harveyi, vibrio anguillarum, vibrio parahaemolyticus and vibrio cholerae, of aquatic products, and can be used for preparation of medicine preventing pathogenic vibrio of the aquatic products.

An object of the present invention is to provide a novel glucose dehydrogenase, a method for producing the glucose dehydrogenase, and applications of the glucose dehydrogenase. The flavin-binding glucose dehydrogenase of the invention has the following characteristics (1) and (4): (1) Molecular weight: the molecular weight of a polypeptide moiety in the enzyme is about 68 kDa as measured by SDS-polyacrylamide electrophoresis; (2) Km value: the Km value for D-glucose is about 15 mM or less; (3) Temperature stability: stable at a temperature of 55° C. or less; and (4) pH stability: stable at a pH range of 3.0 to 8.5.

The invention discloses a series health-care food containing pearl and kudzu root and a preparation method thereof. The food is prepared by matching natural pearl and kudzu root which can be taken both as food and medicine with vitamin, medlar, a sweetening agent and appropriate accessories according to a certain proportion. The health-care food contains organic calcium, inorganic calcium, vitamin and a plurality of trace elements which are needed by human body, and the food further contains components such as flavonoid daidzin, daidzein, xylopuerarin, kudzu powder flavin, and great amount of starch, therefore, the food has the functions of beautifying the face and enlarging the breast, nourishing the tendons and channels and preventing cerebral-cardiovascular diseases, and is taken as health products which are fit for women, the middle aged people and the old, thus delaying senility, strengthening the body and maintaining the beauty and youth of skin.

The invention discloses flavoprotein oxidase genes of macleaya cordata in synthesis of sanguinarine and chelerythrine and application of the flavoprotein oxidase genes. Three flavoprotein oxidase genes joining in synthesis of sanguinarine and chelerythrine are found in a macleaya cordata genome for the first time, including genes Mc20113, Mc6407 and Mc6408. Steps of reaction are respectively verified by using a brewer's yeast system through upstream precursor feeding, and synthesis of sanguinarine and chelerythrine and midbodies can be achieved. The conversion efficiency of same functional genes of macleaya cordata and opium poppy is further compared by using a brewer's yeast heterologous expression system, and the result shows that the conversion rate of the gene of macleaya cordata is remarkably higher than that of opium poppy. The invention further discloses a molecular mechanism of synthesis of sanguinarine in macleaya cordata, and a theoretic basis and molecular assistant breeding targets are provided for breeding of macleaya cordata with high contents of sanguinarine and chelerythrine; and meanwhile, precious experience is provided for in-vitro artificial synthesis of sanguinarine and chelerythrine.

It is intended to highly efficiently produce a large amount of novel FAD-GDH capable of more accurately measuring a glucose level. Provided is a transformant in which a DNA encoding a flavin adenine dinucleotide-binding glucose dehydrogenase selected from the group consisting of (a) a DNA encoding the amino acid sequence of SEQ ID NO: 20; (b) a DNA consisting of the base sequence of SEQ ID NO: 19; (c) a DNA having a base sequence homologous to the base sequence of SEQ ID NO: 19 and encoding a protein having a flavin adenine dinucleotide-binding glucose dehydrogenase activity; (d) a DNA encoding the amino acid sequence of SEQ ID NO: 34; (e) a DNA consisting of the base sequence of SEQ ID NO: 33; and (f) a DNA having a base sequence homologous to the base sequence of SEQ ID NO: 33 and encoding a protein having a flavin adenine dinucleotide-binding glucose dehydrogenase activity has been introduced. Further, a method for producing a flavin adenine dinucleotide-binding glucose dehydrogenase using the transformant is provided.

It is intended to provide a method of diagnosing infection with Chagas disease by screening a trypanocidal drugs for Trypanosoma cruzi which is the pathogen of Chagas disease. Using a flavin protein TcOYE specific to Trypanosoma cruzi, a trypanocidal drugs effective against Trypanosoma cruzi is screened. Using the gene sequence of TcOYE and an antibody therefor, infection with Trypanosoma cruzi is diagnosed.

The object is to provide a novel enzyme which enables to determine the glucose level more accurately, a bacterium capable of producing the enzyme, and use of the enzyme. Disclosed is a flavin adenine dinucleotide-binding glucose dehydrogenase having the following properties (1) to (3):(1) the enzyme has an activity of catalyzing a reaction for oxidizing a hydroxyl group in glucose in the presence of an electron acceptor to produce glucono-delta-lactone; (2) the enzyme has a molecular weight of about 100 kDa as measured by SDS-polyacrylamide gel electrophoresis or about 400 kDa as measured by gel filtration chromatography; and (3) the enzyme is less reactive to maltose, D-fructose, D-mannose and D-galactose. Also disclosed is a microorganism Aspergillus oryzae which can produce the enzyme. Further disclosed are a glucose determination method, a reagent for the determination of glucose, and a kit for the determination of glucose, each utilizing the enzyme.

The invention discloses application of ginkgo biflavonoids to preparation of a medicine for preventing and treating asthma. The ginkgo biflavonoids are at least one of 7-demethylated biflavones, ginkgetin, sciadopitysin, and isoginkgetin. The invention discloses a medicinal composition for preventing and treating the asthma, the composition comprises ginkgo biflavonoids, and further comprises at least one of radix glycyrrhizae, white mulberry root-bark and semen armeniacae amarum. The invention further discloses a pharmaceutical composition formed by mixing ginkgo biflavonoids and a pharmaceutically acceptable excipient, and the mass percent of ginkgo biflavonoids is greater than and equal to 2.5%. The ginkgo biflavonoids can inhibit the recruitment of inflammatory cells in lungs, reduce the expression of inflammatory factors in the lungs, and lower the expression of PI3K-related proteins in inflammation pathways, and are free of obvious toxic or side effects and safe and reliable after being taken for a long term.

The invention discloses a cotton polyamine oxidase GhPAO2 gene and application thereof. The sequence of the cotton polyamine oxidase GhPAO2 gene is shown in SEQ ID No. 3. According to the invention, the root tissue of Jimian 20 is taken as raw material; the whole-length cDAN sequence of the cotton polyamine oxidase GhPAO2 gene is cloned through bioinformatics and the RT-PCR technology; the cotton polyamine oxidase GhPAO2 gene is constructed to a prokaryotic expression vector and expresses a heterologous protein in an escherichia coli Rosetta (DE3) successfully. An in-vitro experiment proves that purified cotton polyamine oxidase GhPAO2 GhPAO2 is a flavoprotein taking FAD as a prothetic group and has the activity of a spermidine oxidase and a spermine oxidase. A bacterial strain capable of expressing the cotton polyamine oxidase GhPAO2 and a contrast bacterial strain containing an empty carrier are treated with sodium chloride solution with different concentrations; with the same treatment, the quantity of cells of the transgenic bacterial strain is remarkably increased when compared with that of the cells of the contrast bacterial strain, which shows the expression of the cotton polyamine oxidase GhPAO2 in the escherichia coli improves the salt tolerance of the host bacteria.

The invention relates to a medicine composition for treating acute or chronic cholecystitis and acute or chronic pancreatitis, which belongs to the field of Chinese medicines and is prepared by saikosaponin 8-15 parts, baicalin 5-12 parts, magnolol 7-16 parts, rheum emodin 1-5 parts, immature total bitter orange flavonoid 9-18 parts, caffeic acid 8-16 parts, paeoniflorin 7-13 parts, chlorogenic acid 10-17 parts, rhizoma pinellinae praeparata 7-13 parts and glycyrrhizic acid 2-7 parts. The medicine composition for treating acute or chronic cholecystitis and acute or chronic pancreatitis has the advantages that the medicine has anti-inflammation, analgesia and antibacterium functions according to Chinese medicine theories and modern pharmacological experimental methods, has a main function of cleaning and discharging liver-gallbladder damp and heat, and is used for acute or chronic cholecystitis and acute or chronic pancreatitis.

The invention discloses a separation preparation process for high-purity irisflorentin. The separation preparation process comprises the following steps of: extracting supercritical CO2 to obtain flavonoid substances; extracting and enriching a solvent to obtain crude products of the irisflorentin; separating by means of preparation type reversed high performance liquid chromatography; and purifying to obtain crystals of the irisflorentin. According to the separation preparation process, flavonoid compounds in vesper iris herb can be continuously extracted, and high-purity irisflorentin monomers can be prepared.

The invention discloses a method for synthesizing a lactam compound. Amino alcohol, alcohol dehydrogenase, flavin molecules, cofactors and catalase react in a solvent. The invention constructs a green and environment-friendly method for enzymatic synthesis of the lactam compound. Compared with common toxic chemical catalysts, the alcohol dehydrogenase is selected as a catalyst, the method has the characteristics of high substrate specificity, no pollution, high catalytic efficiency and the like, the solvent is a buffer aqueous solution, no toxic solvent is used, no by-product is generated, and the product is easy to separate.

The invention discloses a S.japonica (Sw.) Ohwi flavone glucoside injection and its preparing process, wherein the active constituent of the injection is the flavone type compound extracted from Spergularia, the preparing process comprises lixiviating with organic solvent, concentrating the extract through decompression, degreasing for refining, dissolving into soup with water for injection, refrigeration, filtering and deslagging, loading and closing, finally sterilizing and packaging to obtain the finished product.

The invention relates to an extracting method of a blueberry small molecular peptide composition. The method comprises the following steps: (1) pretreatment of raw materials; (2) modification of blueberry protein; (3) composite enzymolysis of blueberry protein; (4) filtration and purification; and (5) dehydration and drying. The blueberry small molecular peptide composition contains small molecular peptide obtained through blueberry protein hydrolysis and provided with molecular weight mainly distributed between 100-700 D, and further comprises chlorogenic acid, citrate, arbutin, myricetin, flavonoids, vitamins and trace-elements, and can be applied to medical raw materials, healthcare food and cosmetics. The molecular weight of the produced obtained through the invention is mainly distributed between 100-700D, the obtained small molecular peptide usually is dipeptide, tripeptide, tetrapeptide or other small molecular structure easily absorbed and utilized by a human body, and the small molecular peptide with molecular weight distributed at 60-700 occupies over 90% of the total weight of the protein.